Aplastic anemia associated with osimertinib: Analysis of the FDA adverse event reporting system
Our analyses generated a safety signal for the association between osimertinib and AA. Further studies are required to understand and confirm the role of osimertinib administration in the development of AA.
Authors
- Daigo Akahane (ORCID: https://orcid.org/0000-0002-9295-1465)
- Seiichiro Katagiri (ORCID: https://orcid.org/0000-0002-3031-9990)
- Katsuhiro Ohyama (ORCID: https://orcid.org/0000-0001-6307-577X)
- Akihiko Gotoh (ORCID: https://orcid.org/0000-0002-8608-4393)
- Yusuke Hori (ORCID: https://orcid.org/0000-0002-5921-3479)
- Shoichi Takahashi
- Hironori Takeuchi
- Hideaki Ayuhara
Publication Details
- Journal
- International Journal of Clinical Pharmacology and Therapeutics
- Published
- 2024-11-20
- DOI
- https://doi.org/10.5414/cp204627
- Citations
- 3
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.36